Nuclear cardiology: Myocardial perfusion imaging with SPECT and PET

Imaging

Volumn 18, Issue 3, 2006, Pages 166-177

  Chua, S C ^a   Ganatra, R H ^a   Green, D J ^a   Groves, A M ^b  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITROGEN 13; OXYGEN 15; RUBIDIUM 82; TETROFOSMIN TC 99M; THALLIUM 201;

BLOOD FLOW VELOCITY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HEART SCINTISCANNING; HUMAN; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 44649158843     PISSN: 09656812     EISSN: None     Source Type: Journal    
DOI: 10.1259/imaging/20803801     Document Type: Review

References (59)

1. Zaret BL, Strauss HW, Martin ND, Wells HP Jr, Flamm MD Jr. Noninvasive regional myocardial perfusion with radio-active potassium. Study of patients at rest, with exercise and during angina pectoris. N Engl J Med 1973;288:809-12.
2. Nott LT. Seminars in Nuclear Cardiology. http://www.commercemarketplace.com/home/nottmarketing/index.html
3. British Heart Foundation 1998. www.bhf.org.uk
4. Donaldson RM, Raphael M, Radley-Smith R, et al. Angiographic identification of primary coronary anomalies causing impaired myocardial perfusion. Cathet Cardiovasc Diagn 1983;9:237-49.
5. Lee YS, Moon DH, Shin JW, et al. Dipyridamole TI-201 SPECT imaging in patients with myocardial bridging. Clin Nucl Med 1999;24:759-64.
6. Fukuda T, Akagi T, Ishibashi M, et al. Non-invasive evaluation of myocardial ischaemia in Kawasaki disease: comparison between dipyridamole stress thallium imaging and exercise stress testing. Am Heart J 1998;135:482-7.
7. Miyagawa M, Mochizuki T, Murase K, et al. Prognostic value of dipyridamole-thallium myocardial scintigraphy in patients with Kawasaki disease. Circulation 1998;98:990-6.
8. Hachamovitch R, Berman DS, Kiat H, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and use in risk stratification. Circulation 1996,93:905-14.
9. Brown KA, Heller GV, Landin RS, et al. Early dipyridamole-(99m) Tc-sestamibi single-photon emission computed tomography imaging 2 to 4 days after acute myocardial infarction predicts in-hospital and post discharge cardiac events: comparison with sub maximal exercise imaging. Circulation 1999;100:2060-6.
10. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update on perioperative cardiovascular evaluation for noncardiac surgery. Circulation 2002;105:1257-67.
11. Heller LI, Cates C, Popma J, et al. Intracoronary Doppler assessment of moderate coronary artery disease. Comparison with Thallium-201 imaging and coronary angiography. Circulation 1997;96:484-90.
12. Zellweger MJ, Lewin HC, Lai S, et al. When to stress patients after coronary artery bypass surgery? Risk stratification in patients early and late post-CABG using stress myocardial perfusion SPECT: implications of appropriate clinical strategies. J Am Coll Cardiol 2001;37:144-52.
13. Loong CY, Anagnostopoulos C. Diagnosis of coronary artery disease by radionuclide myocardial perfusion imaging. Heart 2004;90 Suppl. 5:v2-9.
14. National Institute for Clinical Excellence. Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction. London: National Institute for Clinical Excellence, Technology Appraisal 74, November 2003. www.nice.org.uk
15. Underwood SR, Anagnostopoulos C, Cerqueira M, Ell PJ, Flint EJ, Harbinson M, et al; British Cardiac Society; British Nuclear Cardiology, Soxiety; British Nuclear Medicine Society; Royal College of Physicians of London; Royal College of Radiologists. Myocardial perfusion scintigraphy: the evidence. Eur J Nucl Med Mol Imaging 2004;31:261-91.
16. Kapur A, Latus KA, Davies G, Dhawan RT, Eastick S, Jarritt PH, et al. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study. Eur J Nucl Med Mol Imaging 2002;29:1608-16.
17. Beller GA, Bergmann SR. Myocardial perfusion imaging agents: SPECT and PET. J Nucl Cardiol 2004;11:71-86.
18. Tawarahara K, Kurata C, Tagushi T, et al. Exercise testing and Thallium-201 emission computed tomography in patients with intraventricular conduction disturbances. Am J Cardiol 1992;69:97-102.
19. O'Keefe JH, Bateman TM, Barnhart CS. Adenosine Thallium-201 is superior to exercise Thallium-201 for detecting coronary artery disease in patients with left bundle branch block. J Am Coll Cardiol 1993;21:1332-8.
20. Smits P, Corstens FH, Aengevaeren WR, et al. False-negative dipyridamole Thallium-201 myocardial perfusion imaging after caffeine infusion. J Nucl Med 1991;32:1538-41.
21. Böttcher M, Czemin J, Sun KT, et al. Effect of caffeine on myocardial blood flow at rest and during pharmacological vasodilation. J Nucl Med 1995;36:2016-21.
22. Smits P, Lenders JW, Thien T. Caffeine and theophylline attenuate adenosine-induced vasodilation in humans. Clin Pharmacol Ther 1990;48:410-8.
23. Udelson JE, Heller GV, Wackers F1, Chai A, Hinchman D, Coleman PS, et al. Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging. Circulation 2004;109:457-64.
24. Hays JT, Mahmarian JJ, Cochran AJ, et al. Dobutamine Thallium-201 tomography for evaluating patients with suspected coronary disease unable to undergo exercise or vasodilator pharmacologic stress testing. J Am Coll Cardiol 1993;21:1583-90.
25. Geleijnse M, Elhendy A, Fioretti P, et al. Dobutamine stress myocardial perfusion imaging. J Am Coll Cardiol 2000;36:2017-27.
26. Dubois-Randé JL, Merlet P, Duval-Moulin AM, et al. Coronary vasodilating action of dobutamine in patients with idiopathic dilated cardiomyopathy. Am Heart J 1993;125:1329-36.
27. Bartunek J, Wijns W, Heyndrickx GR, et al. Effects of dobutamine on coronary stenosis physiology and morphology. Comparison with intracoronary adenosine. Circulation 1999;100:243-9.
28. Hicks RJ. Myocardial perfusion scintigraphy techniques using single photon radiotracers. In: Murray E, editor. Nuclear medicine in diagnosis and treatment, 2nd edn. New York, NY: Churchill Livingstone, 1998:1333-51.
29. Pennell DJ, Mavrogeni SI, Forbat SM, Karwatowski SP, Underwood SR. Adenosine combined with dynamic exercise for myocardial perfusion imaging. J Am Coll Cardiol 1995;25:1300-9.
30. Samady H, Wackers FJ, Joska T, Zaret B, Jain D. Pharmacologic stress perfusion imaging with adenosine: role of simultaneous low-level treadmill exercise. J Nucl Cardiol 2002,9:188-96.
31. Thomas GS, Prill NV, Majmundar H, Fabrizi RR, Thomas JJ, Hayashida C, et al. Treadmill exercise during adenosine infusion is safe, results in fewer adverse reactions, and improves myocardial perfusion image quality. J Nucl Cardiol 2000;7:439-46.
32. van Dongen AJ, van Rijk PP. Minimizing liver, bowel, and gastric activity in myocardial perfusion SPECT. J Nucl Med 2000;41:1315-17.
33. 99mTc sestamibi. Clin Nucl Med 1993;18:735-41.
34. Ladenheim ML, Pollock BH, Rozanski A, et al. Extent and severity of myocardial hypoperfusion as predictors of prognosis in patients with suspected coronary artery disease. J Am Coll Cardiol 1986;7:464-71.
35. Weiss AT, Berman DS, Lew AS, et al. Transient ischemic dilation of the left ventricle on stress thallium-201 scintigraphy: a marker of severe and extensive coronary artery disease. J Am Coll Cardiol 1987;9:752-9.
36. Gioia G, Milan E, Giubbini R, DePace N, Heo J, Iskandrian AS. Prognostic value of tomographic rest-redistribution thallium 201 imaging in medically treated patients with coronary artery disease and left ventricular dysfunction. J Nucl Cardiol 1996;3:150-6.
37. Johnson LL, Verdesca SA, Aude WY, et al. Postischemic stunning can affect left ventricular ejection fraction and regional wall motion on post-stress gated sestamibi tomograms. J Am Coll Cardiol 1997;30:1641-8.
38. Gill JB, Ruddy TD, Newell JB, Finkelstein DM, Strauss HW, Boucher CA. Prognostic importance of thallium uptake by the lungs during exercise in coronary artery disease. N Engl J Med 1987;317:1486-9.
39. Angiolillo DJ, Giordano A. Role of myocardial perfusion imaging after coronary revascularization in symptom-free patients: are low-risk patients really low? J Nucl Cardiol 2002;9:550-3.
40. 201T1 gated myocardial perfusion imaging. J Nucl Med 2002; 43:131-9.
41. Matsumoto N, Berman DS, Kavanagh PB, Gerlach J, Hayes SW, Lewin HC, et al. Quantitative assessment of motion artifacts and validation of a new motion correction program for myocardial perfusion SPECT. J Nucl Med 2001;42:687-94.
42. Fitzgerald J, Danias PG. Effect of motion on cardiac SPECT imaging: recognition and motion correction. J Nucl Cardiol 2001;8:701-6.
43. Di Carli MF. Advances in positron emission tomography. J Nucl Cardiol 2004;11:719-32.
44. 99mTc sestarnibi SPECT. J Nucl Cardiol 2006;13:24-33.
45. Dorbala S, Sampson U, Limaye A, et al. Diagnostic value of changes in left ventricular ejection fraction during peak vasodilator stress gated cardiac PET/CT: correlation with the extent of angiographic coronary artery disease. Circulation 2005;112:II-365.
46. Takalkar A, Mavi A, Alavi A, Araujo L. PET in cardiology. Radiol Clin N Am 2005;43:107-19.
47. Beanlands RS, Ruddy TD, Maddahi J. Myocardial viability. In: Wahl, RL, editor. Principles and practice of positron emission tomography. Philadelphia, PA: Lippincott, Williams & Wilkins, 2002:334-50
48. Schelbert HR. Metabolic imaging to assess myocardial viability. J Nucl Med 1994;35(4 Suppl.):8S-14S.
49. Zhang X, Liu XJ, Wu Q Shi R, Gao R, Liu Y, et al. Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial 99mTc-MIBI SPECT and 18F-FDG PET. J Nucl Med 2001;42:1166-73.
50. Bax JJ, Visser FC, Elhendy A, et al. Prediction of improvement of regional left ventricular function after revascularization using different perfusion-metabolic criteria. J Nucl Med 1999;40:1866-73.
51. Noto RB. Cardiac applications of positron emission tomography (PET). Med Health R I 2003;86:139-42.
52. Di Carli MF, Asgarzadie F, Schelbert HR, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995;92:3436-44.
53. Shivalkar B, Maes A, Borgers M, et al. Only hibernating myocardium invariably shows early recovery after coronary revascularization. Circulation 1996;94:308-15.
54. 99mTc-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. J Nucl Med 1997;38:742-8.
55. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. Cardiac applications: myocardial viability. J Nucl Med 2001;42:70S-1S.
56. Schelbert HR. 18-F-Deoxyglucose and the assessment of myocardial viability. Semin Nucl Med 2002;32:60-9.
57. Schwaiger M, Hutchins GD. Evaluation of coronary artery disease with positron emission tomography. Semin Nucl Med 1992;22:210-23.
58. Sampson UK, Atul L, Dorbala S, et al. Diagnostic performance of combined rubidium-82 cardiac positron emission tomography and X-ray computed tomography (PET-CT) in the detection of coronary artery disease. J Am Coll Cardiol 2006;47:11(Suppl. 1):A105.
59. Wahl RL, Townsend DW, Meltzer CC, Von Schulthess GK, Fishman EK. CT/PET Fusion Imaging. Program and abstracts of the 88th Assembly and Scientific Meeting of the Radiological Society of North America; December 1-6, 2002; Chicago, IL. Radiology 2002;225:42.